Exelixis to Co-Host Financial Community Briefing to Discuss Data Presented at the 2018 American Society of Clinical Oncology ...
January 09 2018 - 8:00AM
Business Wire
-- Event to be webcast on www.exelixis.com
--
Exelixis, Inc. (NASDAQ: EXEL) today announced that the company,
along with its partner Ipsen, will host a live briefing event for
the financial community to discuss data presented at the 2018
American Society of Clinical Oncology Gastrointestinal Cancers
Symposium (ASCO-GI). The webcast event will be held following the
closing of the ASCO-GI day's sessions on Friday, January 19, 2018,
beginning at 9:30 p.m. EST / 6:30 p.m. PST (local San Francisco
time).
During the briefing, Exelixis and Ipsen management, along with
an invited guest, will discuss and provide context for the
cabozantinib clinical data presented earlier that day at the
Symposium. Exelixis previously announced that detailed results from
the CELESTIAL trial will be the subject of a late-breaking oral
presentation at ASCO-GI. CELESTIAL is a randomized, double-blind,
placebo-controlled study of cabozantinib versus placebo in patients
with advanced hepatocellular carcinoma who have received prior
treatment with sorafenib.
To access the webcast link, log onto www.exelixis.com and
proceed to the News & Events / Event Calendar page under the
Investors & Media heading. Please connect to the company's
website at least 15 minutes prior to the presentation to ensure
adequate time for any software download that may be required to
listen to the webcast. Alternatively, please call 855-793-2457
(domestic) or 631-485-4921 (international) and provide the
conference call passcode 2478857 to join by phone.
A webcast replay will be archived on www.exelixis.com for one
year. A telephone replay will also be available until 11:59 p.m.
EST on January 26, 2018. Access numbers for the telephone replay
are: 855-859-2056 (domestic) and 404-537-3406 (international); the
passcode is 2478857.
About Exelixis
Founded in 1994, Exelixis, Inc. (NASDAQ: EXEL) is a commercially
successful, oncology-focused biotechnology company that strives to
accelerate the discovery, development and commercialization of new
medicines for difficult-to-treat cancers. Following early work in
model genetic systems, we established a broad drug discovery and
development platform that has served as the foundation for our
continued efforts to bring new cancer therapies to patients in
need. We discovered our lead compounds, cabozantinib and
cobimetinib, and advanced them into clinical development before
entering into partnerships with leading biopharmaceutical companies
in our efforts to bring these medicines to patients globally. We
are steadfast in our commitment to prudently reinvest in our
business to maximize the potential of our pipeline. We intend to
supplement our existing therapeutic assets with targeted business
development activities and internal drug discovery – all to deliver
the next generation of Exelixis medicines and help patients recover
stronger and live longer. Exelixis recently earned a spot on
Deloitte's Technology Fast 500 list, a yearly award program
honoring the 500 fastest-growing companies over the past four
years. For more information about Exelixis, please visit
www.exelixis.com or follow @ExelixisInc on Twitter.
Exelixis and the Exelixis logo are registered
U.S. trademarks.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180109005766/en/
Investors Contact:Exelixis, Inc.Susan Hubbard,
650-837-8194EVP, Public Affairs and Investor
Relationsshubbard@exelixis.comorMedia Contact:For Exelixis,
Inc.Hal Mackins, 415-994-0040hal@torchcommunications.com
Exelixis (NASDAQ:EXEL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Exelixis (NASDAQ:EXEL)
Historical Stock Chart
From Apr 2023 to Apr 2024